Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug ConjugatesBusiness Wire • 02/15/23
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184's Phase 1 Clinical Trial in Q2 2023Business Wire • 01/17/23
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell LymphomaBusiness Wire • 01/05/23
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual MeetingBusiness Wire • 12/15/22
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)Business Wire • 12/13/22
Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ETGlobeNewsWire • 12/02/22
ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results24/7 Wall Street • 11/23/22
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual MeetingBusiness Wire • 11/22/22
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational HighlightsBusiness Wire • 11/07/22
Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ETBusiness Wire • 10/31/22
Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific ConferencesBusiness Wire • 10/25/22
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ETBusiness Wire • 10/21/22
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300Business Wire • 10/20/22
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ETAccesswire • 10/11/22
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual MeetingBusiness Wire • 09/23/22
Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.Business Wire • 09/19/22
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic CancerBusiness Wire • 09/14/22
Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright's 24th Annual Global Investment Conference in September 2022Business Wire • 08/30/22
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 08/19/22
Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational HighlightsBusiness Wire • 08/08/22